Clinical Outcome of Patients With and Without Diabetes Mellitus After Percutaneous Coronary Intervention With the Resolute Zotarolimus-Eluting Stent 2-Year Results From the Prospectively Pooled Analysis of the International Global RESOLUTE Program
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F13%3A43907363" target="_blank" >RIV/00216208:11120/13:43907363 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/13:#0000305
Result on the web
<a href="http://dx.doi.org/10.1016/j.jcin.2012.11.006" target="_blank" >http://dx.doi.org/10.1016/j.jcin.2012.11.006</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jcin.2012.11.006" target="_blank" >10.1016/j.jcin.2012.11.006</a>
Alternative languages
Result language
angličtina
Original language name
Clinical Outcome of Patients With and Without Diabetes Mellitus After Percutaneous Coronary Intervention With the Resolute Zotarolimus-Eluting Stent 2-Year Results From the Prospectively Pooled Analysis of the International Global RESOLUTE Program
Original language description
The aim of this study was to describe the process to obtain Food and Drug Administration (FDA) approval for the expanded indication for treatment with the Resolute zotarolimus-eluting stent (R-ZES) (Medtronic, Inc., Santa Rosa, California) in patients with coronary artery disease and diabetes. Background The R-ZES is the first drug-eluting stent specifically indicated in the United States for percutaneous coronary intervention in patients with diabetes. Methods We pooled patient-level data for 5,130 patients from the RESOLUTE Global Clinical Program. A performance goal prospectively determined in conjunction with the FDA was established as a rate of target vessel failure at 12 months of 14.5%. In addition to the FDA pre-specified cohort of less complexpatients with diabetes (n = 878), we evaluated outcomes of the R-ZES in all 1,535 patients with diabetes compared with all 3,595 patients without diabetes at 2 years. Results The 12-month rate of target vessel failure in the pre-specifie
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of American College of Cardiology: Cardiovascular Interventions
ISSN
1936-8798
e-ISSN
—
Volume of the periodical
6
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
357-368
UT code for WoS article
000317487900009
EID of the result in the Scopus database
—